<p>Pulse Biosciences Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption (IDE), allowing the company to initiate the nPulse Cardiac Catheter Ablation System Study (NANOPULSE-AF) for the treatment of paroxysmal atrial fibrillation (PAF). The approval enables Pulse Biosciences to move forward with clinical evaluation of its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology in the United States. No other organizations are mentioned as recipients of this regulatory approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251218533791) on December 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

PLSE

<p>Pulse Biosciences Inc. has received FDA approval for its IDE, allowing the initiation of the nPulse Cardiac Catheter Ablation System Study for treating paroxysmal atrial fibrillation. This approval enables clinical evaluation of its Nanosecond Pulsed Field Ablation technology in the U.S.</p>

Pulse Biosciences Wins FDA IDE Approval for nPulse Cardiac Catheter Study